The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Open Access
- 1 January 2011
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 13 (4), R115
- https://doi.org/10.1186/ar3400
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?Rheumatic Disease Clinics of North America, 2010
- Tyrosine kinases as targets for the treatment of rheumatoid arthritisNature Reviews Rheumatology, 2009
- Primary B Cell Immunodeficiencies: Comparisons and ContrastsAnnual Review of Immunology, 2009
- Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and PhagocytosisPublished by The American Association of Immunologists ,2008
- Histamine release from human buffy coat-derived mast cellsInternational Immunopharmacology, 2007
- Evolving concepts of rheumatoid arthritisNature, 2003
- Regulation of B Lymphocyte Development and Activation by Bruton's Tyrosine KinaseImmunologic Research, 2001
- Defective B cell development and function in Btk-deficient miceImmunity, 1995
- Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID MiceScience, 1993
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993